Wall Street's M&A Chatter From June 6: Valeant-Bausch & Lomb, Albany Molecular, Horizon Pharma

The following are the M&A deals, rumors and chatter circulating on Wall Street for Tuesday, June 6, 2017.

Valeant in Talks to Sell Surgical Products Business

The Rumor:

Valeant Pharmaceuticals Intl Inc VRX is in talks to sell its Bausch & Lomb unit’s surgical products business to Carl Zeiss Meditec AG, according to sources as reported by Bloomberg. The business could be worth $2 billion in a sale, the sources said.

Representatives for the two companies declined comment.

Valeant closed at $12.56 on Tuesday, up $0.22.

GTCR, Carlyle Acquire Albany Molecular Research for $21.75/Share

The Deal:

Albany Molecular Research, Inc. AMRI confirmed it has agreed to be acquired by affiliates of The Carlyle Group LP CG and GTCR LLC for $21.75 per share in cash. The deal is expected to close shortly after a vote by AMRI shareholders in Q3 of 2017.

Albany Molecular Research closed at $21.53, up $1.76.

Horizon Pharma Exploring Sale

The Rumor:

Shares of Horzion Pharma PLC HZNP spiked to a high of $11.44 midday Tuesday, on a report from Betaville that the company could be for sale. Horizon acquired Raptor Pharmaceutical in 2016, but failed in a bid to acquire Depomed DEPO.

Horizon Pharma closed at $11.04, up $0.12.